Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.

Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. Abstract Text:

INTRODUCTION: Finding new immunohistochemical markers that are specific to hereditary breast cancer could help us to select candidates for BRCA1/BRCA2 mutation testing and to understand the biological pathways of tumour development. METHODS: Using breast cancer tumour microarrays, immunohistochemical expression of cytokeratin (CK)-5/6, CK-14 and CK-17 was evaluated in breast tumours from BRCA1 families (n = 46), BRCA2 families (n = 40), non-BRCA1/BRCA2 families (n = 358) and familial breast cancer patients with one first-degree relative affected by breast or ovarian cancer (n = 270), as well as from patients with sporadic breast cancer (n = 364). Staining for CK-5/6, CK-14 and CK-17 was compared between these groups and correlated with other clinical and histological factors. RESULTS: CK-5/6, CK-14 and CK-17 were detected mostly among oestrogen receptor (ER)-negative, progesterone receptor (PR)-negative and high-grade tumours. We found the highest percentages of samples positive for these CKs among ER-negative/HER2-negative tumours. In univariate analysis, CK-14 was significantly associated with tumours from BRCA1 (39%; P < 0.0005), BRCA2 (27%; P = 0.011), and non-BRCA1/BRCA2 (21%; P < 0.005) families, as compared with sporadic tumours (10%). However, in multivariate analysis, CKs were not found to be independently associated with BRCA1 or BRCA2 mutation status, and the most effective predictors of BRCA1 mutations were age at onset, HER2 status, and either ER or PR status. CONCLUSION: Although our study confirms that basal CKs can help to identify BRCA1 mutation carriers, this effect was weaker than previously suggested and CKs did not independently predict BRCA1 mutation either from sporadic or familial breast cancer cases. The most effective, independent predictors of BRCA1 mutations were age at onset, HER2 status, and either ER or PR status, as compared with sporadic or non-BRCA1/BRCA2 cancers.

Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Breast cancer research : BCR

VOLUME: 10

Page Numbers: R17

Journal Abbreviation: Breast Cancer Res.

ISSN: 1465-542X

DAY: 14

MONTH: 02

YEAR: 2008

Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100927353

Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.

AFFILIATION: Department of Oncology, Helsinki University Central Hospital, Haartmaninkatu, 00029 HUS, Helsinki Finland. hannaleena.eerola@fimnet.fi

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Breast Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families Related Publications

• A case of foetal bleeding into maternal circulation.
• Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.
• Blood transfusion and Rh immunization.
• Classification principles and genetics of chronic gastritis.
• Comprehensive analysis of NuMA variation in breast cancer.
• Haemophilia A in a girl. A probable exception from sex-linked recessive inheritance.
• Immunosuppressive therapy in Rh-incompatible transfusion.
• NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer.
• On the factors affecting maternal Rh immunization.
• RH: serology and clinic.
• The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer.
• The occurrence of kernicterus in an autopsy material.
• [A review of the activities of the Finnish Medical Association during the 1st half of 1966]
• [New regulations on specialization]
• [The doctor in the sickroom.]
• [The shortage of doctors and its correction]